Review



lpa 1 receptor antagonist am095  (ApexBio)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    ApexBio lpa 1 receptor antagonist am095
    Inhibition of LPA 1 mitigates disease severity in EAN. a Active EAN was induced in Lewis rats, which were treated with the LPA 1 receptor antagonist <t>AM095</t> once daily after developing first clinical symptoms at 10 dpi. While there was no significant impact of AM095 around the peak of disease, disease severity was significantly ameliorated over the course of the remission phase. A significant difference was observed from 20 dpi until the end of the experiment at 28 dpi. Each dot indicates mean clinical scores ± s.e.m. b Cumulative clinical scores of individual animals obtained from day 0 to the end of the experiment at 28 dpi. Animals were pooled from three independent experiments. N = 21 (Vehicle)/23 (AM095). c Representative images of semi-thin toluidine blue-stained sections of sciatic nerves at 28 dpi. d Axon diameter histogram indicates a significant increase in the number of large-caliber (≥ 8 µm) myelinated axons following AM095 treatment ( N = 4). e G-ratios were plotted against axon diameters; overlapping results indicate comparability of both treatment groups with regard to axon diameter distributions and myelination. f In accordance with this finding, the assessment of g-ratios (the numerical ratio between axonal and myelinated fiber diameter) does not indicate any differences with regard to myelin thickness ( N = 4). Data represent mean ± s.e.m. P ≤ 0.05*. Scale bar indicates 50 µm
    Lpa 1 Receptor Antagonist Am095, supplied by ApexBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/lpa+1+receptor+antagonist+am095/pmc08680309-44-1-11?v=ApexBio
    Average 90 stars, based on 1 article reviews
    lpa 1 receptor antagonist am095 - by Bioz Stars, 2026-08
    90/100 stars

    Images

    1) Product Images from "LPA 1 signaling drives Schwann cell dedifferentiation in experimental autoimmune neuritis"

    Article Title: LPA 1 signaling drives Schwann cell dedifferentiation in experimental autoimmune neuritis

    Journal: Journal of Neuroinflammation

    doi: 10.1186/s12974-021-02350-5

    Inhibition of LPA 1 mitigates disease severity in EAN. a Active EAN was induced in Lewis rats, which were treated with the LPA 1 receptor antagonist AM095 once daily after developing first clinical symptoms at 10 dpi. While there was no significant impact of AM095 around the peak of disease, disease severity was significantly ameliorated over the course of the remission phase. A significant difference was observed from 20 dpi until the end of the experiment at 28 dpi. Each dot indicates mean clinical scores ± s.e.m. b Cumulative clinical scores of individual animals obtained from day 0 to the end of the experiment at 28 dpi. Animals were pooled from three independent experiments. N = 21 (Vehicle)/23 (AM095). c Representative images of semi-thin toluidine blue-stained sections of sciatic nerves at 28 dpi. d Axon diameter histogram indicates a significant increase in the number of large-caliber (≥ 8 µm) myelinated axons following AM095 treatment ( N = 4). e G-ratios were plotted against axon diameters; overlapping results indicate comparability of both treatment groups with regard to axon diameter distributions and myelination. f In accordance with this finding, the assessment of g-ratios (the numerical ratio between axonal and myelinated fiber diameter) does not indicate any differences with regard to myelin thickness ( N = 4). Data represent mean ± s.e.m. P ≤ 0.05*. Scale bar indicates 50 µm
    Figure Legend Snippet: Inhibition of LPA 1 mitigates disease severity in EAN. a Active EAN was induced in Lewis rats, which were treated with the LPA 1 receptor antagonist AM095 once daily after developing first clinical symptoms at 10 dpi. While there was no significant impact of AM095 around the peak of disease, disease severity was significantly ameliorated over the course of the remission phase. A significant difference was observed from 20 dpi until the end of the experiment at 28 dpi. Each dot indicates mean clinical scores ± s.e.m. b Cumulative clinical scores of individual animals obtained from day 0 to the end of the experiment at 28 dpi. Animals were pooled from three independent experiments. N = 21 (Vehicle)/23 (AM095). c Representative images of semi-thin toluidine blue-stained sections of sciatic nerves at 28 dpi. d Axon diameter histogram indicates a significant increase in the number of large-caliber (≥ 8 µm) myelinated axons following AM095 treatment ( N = 4). e G-ratios were plotted against axon diameters; overlapping results indicate comparability of both treatment groups with regard to axon diameter distributions and myelination. f In accordance with this finding, the assessment of g-ratios (the numerical ratio between axonal and myelinated fiber diameter) does not indicate any differences with regard to myelin thickness ( N = 4). Data represent mean ± s.e.m. P ≤ 0.05*. Scale bar indicates 50 µm

    Techniques Used: Inhibition, Staining

    Minor impact of AM095 treatment on immune cell infiltration. Immune cell infiltration was assessed by counting the number of CD3 + (T-lymphocytes) and CD11b/c + (myeloid cells) on sciatic nerve sections in randomly selected fields. a Representative images of immune cell infiltration at peak of disease at 14 dpi, and early remission phase at 21 dpi. b + c No significant difference was observed in the number of infiltrating CD3+ cells between peak of disease and remission phase ( N = 9/8/4/4 from left to right). d + e While there was no significant reduction in CD3 + cells at 14 dpi, we recognized a slight decrease in myeloid cells under AM095 at 21 dpi ( N = 5/5/5/6 from left to right)). Cell counts were normalized to area. Data represent mean ± s.e.m. P ≤ 0.05*. Scale bars indicate 50 µm
    Figure Legend Snippet: Minor impact of AM095 treatment on immune cell infiltration. Immune cell infiltration was assessed by counting the number of CD3 + (T-lymphocytes) and CD11b/c + (myeloid cells) on sciatic nerve sections in randomly selected fields. a Representative images of immune cell infiltration at peak of disease at 14 dpi, and early remission phase at 21 dpi. b + c No significant difference was observed in the number of infiltrating CD3+ cells between peak of disease and remission phase ( N = 9/8/4/4 from left to right). d + e While there was no significant reduction in CD3 + cells at 14 dpi, we recognized a slight decrease in myeloid cells under AM095 at 21 dpi ( N = 5/5/5/6 from left to right)). Cell counts were normalized to area. Data represent mean ± s.e.m. P ≤ 0.05*. Scale bars indicate 50 µm

    Techniques Used:

    Hemogram profiles indicate no impact of AM095 a circulating leukocytes. At 21 dpi, hemogram profiles were generated from blood samples taken by cardiac puncture immediately after animals were sacrificed. No differences were detected in basic parameters including a erythrocytes, hemoglobin (HGB), hematocrit (HCT) and b platelets. c The total number of circulating leukocytes was unaffected by treatment with AM095. d Coherently, no significant differences were observed for subpopulations including lymphocytes, neutrophils, monocytes, eosinophils and basophils. Data represent mean ± s.e.m. N = 7 for each column
    Figure Legend Snippet: Hemogram profiles indicate no impact of AM095 a circulating leukocytes. At 21 dpi, hemogram profiles were generated from blood samples taken by cardiac puncture immediately after animals were sacrificed. No differences were detected in basic parameters including a erythrocytes, hemoglobin (HGB), hematocrit (HCT) and b platelets. c The total number of circulating leukocytes was unaffected by treatment with AM095. d Coherently, no significant differences were observed for subpopulations including lymphocytes, neutrophils, monocytes, eosinophils and basophils. Data represent mean ± s.e.m. N = 7 for each column

    Techniques Used: Generated

    AM095 treatment decreases the number of dedifferentiating Schwann cells. Schwann cell dedifferentiation was investigated via immunohistochemistry by counting the number Sox2-positive cells in randomly selected fields on sciatic nerve sections. a + b A significant reduction of Sox2-positive cells with AM095 was observed at 21 dpi ( N = 5/5). c + d This effect was even more pronounced at 28 dpi ( N = 8/8). e + f In accordance with this finding, the number of differentiated Sox10-positive cells was significantly increased under treatment with AM095 at 28 dpi ( N = 8/8). The number of Sox2/10-positive cells was related to the total number of cells stained with DAPI and normalized to vehicle-treated controls. Data represent normalized mean ± s.e.m. P ≤ 0.05*, P ≤ 0.01**. Scale bars indicate 50 µm
    Figure Legend Snippet: AM095 treatment decreases the number of dedifferentiating Schwann cells. Schwann cell dedifferentiation was investigated via immunohistochemistry by counting the number Sox2-positive cells in randomly selected fields on sciatic nerve sections. a + b A significant reduction of Sox2-positive cells with AM095 was observed at 21 dpi ( N = 5/5). c + d This effect was even more pronounced at 28 dpi ( N = 8/8). e + f In accordance with this finding, the number of differentiated Sox10-positive cells was significantly increased under treatment with AM095 at 28 dpi ( N = 8/8). The number of Sox2/10-positive cells was related to the total number of cells stained with DAPI and normalized to vehicle-treated controls. Data represent normalized mean ± s.e.m. P ≤ 0.05*, P ≤ 0.01**. Scale bars indicate 50 µm

    Techniques Used: Immunohistochemistry, Staining



    Similar Products

    lpa 1 receptor antagonist am095  (ApexBio)
    90
    ApexBio lpa 1 receptor antagonist am095
    Inhibition of LPA 1 mitigates disease severity in EAN. a Active EAN was induced in Lewis rats, which were treated with the LPA 1 receptor antagonist <t>AM095</t> once daily after developing first clinical symptoms at 10 dpi. While there was no significant impact of AM095 around the peak of disease, disease severity was significantly ameliorated over the course of the remission phase. A significant difference was observed from 20 dpi until the end of the experiment at 28 dpi. Each dot indicates mean clinical scores ± s.e.m. b Cumulative clinical scores of individual animals obtained from day 0 to the end of the experiment at 28 dpi. Animals were pooled from three independent experiments. N = 21 (Vehicle)/23 (AM095). c Representative images of semi-thin toluidine blue-stained sections of sciatic nerves at 28 dpi. d Axon diameter histogram indicates a significant increase in the number of large-caliber (≥ 8 µm) myelinated axons following AM095 treatment ( N = 4). e G-ratios were plotted against axon diameters; overlapping results indicate comparability of both treatment groups with regard to axon diameter distributions and myelination. f In accordance with this finding, the assessment of g-ratios (the numerical ratio between axonal and myelinated fiber diameter) does not indicate any differences with regard to myelin thickness ( N = 4). Data represent mean ± s.e.m. P ≤ 0.05*. Scale bar indicates 50 µm
    Lpa 1 Receptor Antagonist Am095, supplied by ApexBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/lpa+1+receptor+antagonist+am095/pmc08680309-44-1-11?v=ApexBio
    Average 90 stars, based on 1 article reviews
    lpa 1 receptor antagonist am095 - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Inhibition of LPA 1 mitigates disease severity in EAN. a Active EAN was induced in Lewis rats, which were treated with the LPA 1 receptor antagonist AM095 once daily after developing first clinical symptoms at 10 dpi. While there was no significant impact of AM095 around the peak of disease, disease severity was significantly ameliorated over the course of the remission phase. A significant difference was observed from 20 dpi until the end of the experiment at 28 dpi. Each dot indicates mean clinical scores ± s.e.m. b Cumulative clinical scores of individual animals obtained from day 0 to the end of the experiment at 28 dpi. Animals were pooled from three independent experiments. N = 21 (Vehicle)/23 (AM095). c Representative images of semi-thin toluidine blue-stained sections of sciatic nerves at 28 dpi. d Axon diameter histogram indicates a significant increase in the number of large-caliber (≥ 8 µm) myelinated axons following AM095 treatment ( N = 4). e G-ratios were plotted against axon diameters; overlapping results indicate comparability of both treatment groups with regard to axon diameter distributions and myelination. f In accordance with this finding, the assessment of g-ratios (the numerical ratio between axonal and myelinated fiber diameter) does not indicate any differences with regard to myelin thickness ( N = 4). Data represent mean ± s.e.m. P ≤ 0.05*. Scale bar indicates 50 µm

    Journal: Journal of Neuroinflammation

    Article Title: LPA 1 signaling drives Schwann cell dedifferentiation in experimental autoimmune neuritis

    doi: 10.1186/s12974-021-02350-5

    Figure Lengend Snippet: Inhibition of LPA 1 mitigates disease severity in EAN. a Active EAN was induced in Lewis rats, which were treated with the LPA 1 receptor antagonist AM095 once daily after developing first clinical symptoms at 10 dpi. While there was no significant impact of AM095 around the peak of disease, disease severity was significantly ameliorated over the course of the remission phase. A significant difference was observed from 20 dpi until the end of the experiment at 28 dpi. Each dot indicates mean clinical scores ± s.e.m. b Cumulative clinical scores of individual animals obtained from day 0 to the end of the experiment at 28 dpi. Animals were pooled from three independent experiments. N = 21 (Vehicle)/23 (AM095). c Representative images of semi-thin toluidine blue-stained sections of sciatic nerves at 28 dpi. d Axon diameter histogram indicates a significant increase in the number of large-caliber (≥ 8 µm) myelinated axons following AM095 treatment ( N = 4). e G-ratios were plotted against axon diameters; overlapping results indicate comparability of both treatment groups with regard to axon diameter distributions and myelination. f In accordance with this finding, the assessment of g-ratios (the numerical ratio between axonal and myelinated fiber diameter) does not indicate any differences with regard to myelin thickness ( N = 4). Data represent mean ± s.e.m. P ≤ 0.05*. Scale bar indicates 50 µm

    Article Snippet: The LPA 1 receptor antagonist AM095 [ ] was obtained from ApexBio (Houston, TX, USA) and dissolved in phosphate buffered saline (PBS) containing 0.5% methylcellulose (Sigma-Aldrich).

    Techniques: Inhibition, Staining

    Minor impact of AM095 treatment on immune cell infiltration. Immune cell infiltration was assessed by counting the number of CD3 + (T-lymphocytes) and CD11b/c + (myeloid cells) on sciatic nerve sections in randomly selected fields. a Representative images of immune cell infiltration at peak of disease at 14 dpi, and early remission phase at 21 dpi. b + c No significant difference was observed in the number of infiltrating CD3+ cells between peak of disease and remission phase ( N = 9/8/4/4 from left to right). d + e While there was no significant reduction in CD3 + cells at 14 dpi, we recognized a slight decrease in myeloid cells under AM095 at 21 dpi ( N = 5/5/5/6 from left to right)). Cell counts were normalized to area. Data represent mean ± s.e.m. P ≤ 0.05*. Scale bars indicate 50 µm

    Journal: Journal of Neuroinflammation

    Article Title: LPA 1 signaling drives Schwann cell dedifferentiation in experimental autoimmune neuritis

    doi: 10.1186/s12974-021-02350-5

    Figure Lengend Snippet: Minor impact of AM095 treatment on immune cell infiltration. Immune cell infiltration was assessed by counting the number of CD3 + (T-lymphocytes) and CD11b/c + (myeloid cells) on sciatic nerve sections in randomly selected fields. a Representative images of immune cell infiltration at peak of disease at 14 dpi, and early remission phase at 21 dpi. b + c No significant difference was observed in the number of infiltrating CD3+ cells between peak of disease and remission phase ( N = 9/8/4/4 from left to right). d + e While there was no significant reduction in CD3 + cells at 14 dpi, we recognized a slight decrease in myeloid cells under AM095 at 21 dpi ( N = 5/5/5/6 from left to right)). Cell counts were normalized to area. Data represent mean ± s.e.m. P ≤ 0.05*. Scale bars indicate 50 µm

    Article Snippet: The LPA 1 receptor antagonist AM095 [ ] was obtained from ApexBio (Houston, TX, USA) and dissolved in phosphate buffered saline (PBS) containing 0.5% methylcellulose (Sigma-Aldrich).

    Techniques:

    Hemogram profiles indicate no impact of AM095 a circulating leukocytes. At 21 dpi, hemogram profiles were generated from blood samples taken by cardiac puncture immediately after animals were sacrificed. No differences were detected in basic parameters including a erythrocytes, hemoglobin (HGB), hematocrit (HCT) and b platelets. c The total number of circulating leukocytes was unaffected by treatment with AM095. d Coherently, no significant differences were observed for subpopulations including lymphocytes, neutrophils, monocytes, eosinophils and basophils. Data represent mean ± s.e.m. N = 7 for each column

    Journal: Journal of Neuroinflammation

    Article Title: LPA 1 signaling drives Schwann cell dedifferentiation in experimental autoimmune neuritis

    doi: 10.1186/s12974-021-02350-5

    Figure Lengend Snippet: Hemogram profiles indicate no impact of AM095 a circulating leukocytes. At 21 dpi, hemogram profiles were generated from blood samples taken by cardiac puncture immediately after animals were sacrificed. No differences were detected in basic parameters including a erythrocytes, hemoglobin (HGB), hematocrit (HCT) and b platelets. c The total number of circulating leukocytes was unaffected by treatment with AM095. d Coherently, no significant differences were observed for subpopulations including lymphocytes, neutrophils, monocytes, eosinophils and basophils. Data represent mean ± s.e.m. N = 7 for each column

    Article Snippet: The LPA 1 receptor antagonist AM095 [ ] was obtained from ApexBio (Houston, TX, USA) and dissolved in phosphate buffered saline (PBS) containing 0.5% methylcellulose (Sigma-Aldrich).

    Techniques: Generated

    AM095 treatment decreases the number of dedifferentiating Schwann cells. Schwann cell dedifferentiation was investigated via immunohistochemistry by counting the number Sox2-positive cells in randomly selected fields on sciatic nerve sections. a + b A significant reduction of Sox2-positive cells with AM095 was observed at 21 dpi ( N = 5/5). c + d This effect was even more pronounced at 28 dpi ( N = 8/8). e + f In accordance with this finding, the number of differentiated Sox10-positive cells was significantly increased under treatment with AM095 at 28 dpi ( N = 8/8). The number of Sox2/10-positive cells was related to the total number of cells stained with DAPI and normalized to vehicle-treated controls. Data represent normalized mean ± s.e.m. P ≤ 0.05*, P ≤ 0.01**. Scale bars indicate 50 µm

    Journal: Journal of Neuroinflammation

    Article Title: LPA 1 signaling drives Schwann cell dedifferentiation in experimental autoimmune neuritis

    doi: 10.1186/s12974-021-02350-5

    Figure Lengend Snippet: AM095 treatment decreases the number of dedifferentiating Schwann cells. Schwann cell dedifferentiation was investigated via immunohistochemistry by counting the number Sox2-positive cells in randomly selected fields on sciatic nerve sections. a + b A significant reduction of Sox2-positive cells with AM095 was observed at 21 dpi ( N = 5/5). c + d This effect was even more pronounced at 28 dpi ( N = 8/8). e + f In accordance with this finding, the number of differentiated Sox10-positive cells was significantly increased under treatment with AM095 at 28 dpi ( N = 8/8). The number of Sox2/10-positive cells was related to the total number of cells stained with DAPI and normalized to vehicle-treated controls. Data represent normalized mean ± s.e.m. P ≤ 0.05*, P ≤ 0.01**. Scale bars indicate 50 µm

    Article Snippet: The LPA 1 receptor antagonist AM095 [ ] was obtained from ApexBio (Houston, TX, USA) and dissolved in phosphate buffered saline (PBS) containing 0.5% methylcellulose (Sigma-Aldrich).

    Techniques: Immunohistochemistry, Staining